- Home
- CLDI vs MRKR Comparison
CLDI vs MRKR Comparison
Compare CLDI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- MRKR
- Stock Information
- Founded
- CLDI 2014
- MRKR N/A
- Country
- CLDI United States
- MRKR United States
- Employees
- CLDI N/A
- MRKR N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- MRKR Health Care
- Exchange
- CLDI Nasdaq
- MRKR Nasdaq
- Market Cap
- CLDI 15.7M
- MRKR 13.4M
- IPO Year
- CLDI N/A
- MRKR N/A
- Fundamental
- Price
- CLDI $0.40
- MRKR $1.12
- Analyst Decision
- CLDI Strong Buy
- MRKR Strong Buy
- Analyst Count
- CLDI 2
- MRKR 3
- Target Price
- CLDI $15.00
- MRKR $13.17
- AVG Volume (30 Days)
- CLDI 202.0K
- MRKR 39.8K
- Earning Date
- CLDI 05-20-2025
- MRKR 05-27-2025
- Dividend Yield
- CLDI N/A
- MRKR N/A
- EPS Growth
- CLDI N/A
- MRKR N/A
- EPS
- CLDI N/A
- MRKR N/A
- Revenue
- CLDI N/A
- MRKR $6,591,080.00
- Revenue This Year
- CLDI N/A
- MRKR N/A
- Revenue Next Year
- CLDI N/A
- MRKR N/A
- P/E Ratio
- CLDI N/A
- MRKR N/A
- Revenue Growth
- CLDI N/A
- MRKR 99.06
- 52 Week Low
- CLDI $0.35
- MRKR $0.95
- 52 Week High
- CLDI $4.90
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- CLDI 36.62
- MRKR 46.59
- Support Level
- CLDI $0.40
- MRKR $1.09
- Resistance Level
- CLDI $0.46
- MRKR $1.30
- Average True Range (ATR)
- CLDI 0.04
- MRKR 0.08
- MACD
- CLDI 0.00
- MRKR -0.00
- Stochastic Oscillator
- CLDI 9.73
- MRKR 26.19
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.